<DOC>
	<DOCNO>NCT00004993</DOCNO>
	<brief_summary>Glucocorticoids potent anti-inflammatory immunosuppressive agent . However , prolong use potent agent result severe bone loss osteoporotic fracture . Parathyroid hormone ( 1-34 ) , give daily injection find dramatically increase bone mass osteoporotic animal postmenopausal woman . The purpose study determine whether 2 year daily PTH ( 1-34 ) injection increase bone mass reduce development new fracture . In addition , follow study subject 2 year determine type anti-resorptive agent require maintain newly form bone . We enrol postmenopausal woman chronic corticosteroid therapy ( prednisone etc . ) bone loss ( osteopenia DXA ) part four-year-long study . The patient receive two-year therapy either PTH ( 1-34 ) placebo , second part study subject receive either estrogen placebo alendronate placebo . We measure bone gain standard bone densitometry , special x-rays spine hip , serum urine bone marker .</brief_summary>
	<brief_title>Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Postmenopausal woman glucocorticoid ( prednisone 5mg/d great Osteopenia T score hip lumbar spine 2.0 All study subject must stable dose estrogen/progesterone raloxifene Ambulatory able come clinical center 9 time 2 year Willing sign inform consent Generalized disease bone ( glucocorticoidinduced osteoporosis ) , include hyperparathyroidism , hyperthyroidism , Paget 's disease ) Diseases affect bone metabolism ( e.g . alcoholism , inflammatory bowel disease , malabsorption , renal disease ( Cr2 ) liver disease ( transaminase level 2 time limit normal ) Within past 1 year , regular use medication know affect bone metabolism ( e.g . anabolic steroid , anticoagulant , anticonvulsant , pharmacologic dos vitamin D vitamin A supplement ) . History drug abuse Senile dementia , paraplegia and/or quadriplegia Unstable rheumatic disease clinically significant renal central nervous system involvement .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Parathyroid hormone ( 1-34 )</keyword>
	<keyword>Glucocorticoid-induced osteoporosis</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>osteoporotic fracture</keyword>
</DOC>